News

Ideas That Generate Results

According to a new research report by RNCOS entitled, “Indian NIPT Market Outlook 2022”, amongst the key players in this industry, MedGenome has monopolized the market. MedGenome was the first company to introduce NIPT test by launching sample testing facility in India.
 
In October 2015, MedGenome collaborated with Natera for providing Panorama test in India.  Since then, the company has been contributing the maximum share to the Indian NIPT market and has also performed 1000 free NIPT test to identify the pattern of chromosomal abnormalities in fetus.  
 
MedGenome’s well equipped research lab in Bengaluru performs the Panorama test in India thus, introducing a quality intensive and cost effective genetic testing. The test is available at a cost of INR 30,000.
 
MedGenome is also planning to expand its non invasive prenatal screening test to reach 200 cities in the country during 2016-2017. Company has also taken various initiatives to expand its portfolio of genetic tests, enhance sequencing facilities in India and the US, and expand its collaborative network with specialty hospitals/clinics and genomic research institutions in India. 
 
Research Analysis and Highlights
 
The report provides the potential market for NIPT in India. Furthermore, the report also provides a depiction of macro-economic factors, healthcare infrastructure and population demographics to assess the industry potential and growth. The report also covers a brief description regarding the available NIPT tests in India as well as in global market. Moreover, regulatory scenario has been prudently analyzed to reflect a clear picture of the immense possibilities in the Indian NIPT market.
 
The report also covers detailed information about the prominent players in the global as well as Indian market with a brief business overview and analysis of their strengths and weaknesses, which will act as a pristine source of business intelligence for players looking to enter the highly lucrative Indian NIPT market. Besides, detailed profiling of Indian pathology labs and IVF clinics will help the medical centers who are seeking for partnerships and collaborations to make an informed decision.
 
Some of the key highlights of the report include the following:

 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM856.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm